ArticleJournal of cancer research and clinical oncology2023

Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.

Jung Yeon Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.